Stocks finished higher Tuesday with Wall Street clawing back losses from Monday's selloff as investors turned their attention to a slew of earnings reports.
Here are some of the top gainers for Tuesday:
1. Alcoa | Increase 11%
Shares of Alcoa (AA) - Get Alcoa Corporation Report rose after aluminum titan was upgraded to conviction buy from buy at Goldman Sachs. Analyst Emily Chieng said Alcoa has "significant leverage to a positive commodity price outlook," where every 10% increase in aluminum prices corresponds to a 20% increase in Ebitda, according to the Fly.
2. Chubb | Increase 4.3%
Chubb (CB) - Get Chubb Limited Report shares advanced after the insurance company's board approved a new one-time incremental share repurchase program of up to $5 billion through June 30, 2022. The company said its current buyback authorization of $2.5 billion has $65 million remaining, which would be used prior to the latest program.
3. Dish Network | Increase 4.7%
Dish Network (DISH) - Get DISH Network Corporation Class A Report climbed after the satellite television service provider said it had signed a deal valued at a minimum $5 billion to make AT&T (T) - Get AT&T Inc. Report the primary network-services partner for its wireless customers. Under the terms of the 10-year deal, AT&T will provide voice, data, messaging services to customers of Dish-owned mobile virtual network operators Boost Mobile, Ting and Republic Wireless.
4. HCA Healthcare | Increase 14%
HCA Healthcare (HCA) - Get HCA Healthcare Inc Report jumped after the hospital operator beat Wall Street's second-quarter earnings expectations. Net income came to $1.45 billion, or $4.36 a share. The FactSet consensus called for earnings of $3.16 a share. Revenue totaled $14.43 billion, up from $11.07 a year earlier and beating FactSet's consensus of $13.6 billion.
5. Immunome | Increase 9%
Immunome (IMNM) - Get Immunome, Inc. Report shares rose after the biopharmaceutical company said its three-antibody cocktail, IMM-BCP-01, demonstrated "potent neutralizing activity" against the COVID-19 delta variant in preclinical pseudovirus testing. The company said in February that it had isolated antibodies that could blunt several COVID types.